

ASX Announcement | 26 October 2023
Althea Group Holdings (ASX:AGH)

Althea THC20:CBD1 approved for reimbursement in Ireland

Highlights:

- The Republic of Ireland's Primary Care Reimbursement Service has approved Althea THC20:CBD1 for reimbursement in Ireland
- Althea THC20:CBD1 will be reimbursed for intractable nausea and vomiting associated with chemotherapy
- Althea is the only supplier with multiple cannabis oils approved for reimbursement in Ireland (Althea THC20:CBD1 & Althea CBD12:THC10)
- MyAccess Clinics will offer consultations to patients in Ireland commencing November 2023

26 October 2023: **Althea Group Holdings Limited (ASX:AGH) ('AGH', or 'the Company')**, a global leader in the manufacturing, sales and distribution of cannabis-based medicines and recreational cannabis products, is pleased to announce that Ireland's Primary Care Reimbursement Service ('PCRS') has approved **Althea THC20:CBD1** for reimbursement in Ireland. Additionally, MyAccess Clinics will offer consultations to patients in Ireland commencing November 2023.

Reimbursement approval for intractable nausea and vomiting associated with chemotherapy (CINV)

In a follow up to the Company's ASX announcement on 19 May 2023, Althea THC20:CBD1 has now been added to the PCRS in the Republic of Ireland, making it free of charge for Irish patients being treated for CINV.

The Rapid Review Submission for Althea THC20:CBD1 cannabis oil (50 ml), as included in Schedule 1 of the Misuse of Drugs (Prescription and Control of Supply of Cannabis for Medical Use) (Amendment) Regulations 2023, has resulted in the assignment of administrative codes to facilitate access to the product in line with the Misuse of Drugs (Prescription and Control of Supply of Cannabis for Medical Use) Regulations 2019 (as amended) for the specified therapeutic indication of CINV.

Controlling chemotherapy-induced nausea and vomiting (CINV) is critical to ensure adherence with chemotherapy and reduce morbidity and total healthcare costs¹.

The agreed reimbursement price for Althea THC20:CBD1 (50ml) is €330, or approximately AUD\$552.

MyAccess Clinics to launch in Ireland in November 2023

A subsidiary of AGH, MyAccess Clinics is a private medical clinic specialising in medicinal cannabis, offering convenient and affordable online consultations for patients. MyAccess Clinics' Healthcare Professionals will be available to consult with Irish patients commencing November 2023, with prescriptions fulfilled electronically and medicines delivered by mail. The Irish expansion will utilize existing infrastructure and does not require any additional capital expenditure.

¹ 1. Piechotta V, Adams A, Haque M, et al. *Cochrane Database Syst Rev.* 2021;11(11):CD012775. 2. Natale JJ. *Am J Manag Care.* 2018;24(18 Suppl):S391-S397.



AGH CEO, Joshua Fegan said: “The addition of Althea THC20:CBD1 to the Primary Care Reimbursement Service in Ireland is another remarkable achievement for Althea and solidifies our position as the global leader in the sale and distribution of medicinal cannabis extracts. MyAccess Clinics has already serviced thousands of patients in the UK, and we look forward to offering an excellent service to our deserved patients in Ireland.”

-ENDS-

Authorised by: Robert Meissner, Company Secretary

For further information, please contact:

Althea Group Holdings Ltd

Joshua Fegan

CEO & Managing Director

M: 1300 70 20 20

E: contact@althea.life

Media & Investor Enquiries

Media & Investor Relations

P: +613 9650 5096

E: investors@althea.life

Althea Group Holdings Limited (ASX:AGH)

Althea Group Holdings Ltd ('AGH') is a global leader in the manufacturing, sales and distribution of cannabis-based medicines and recreational cannabis products. AGH services these sectors via two distinct business units. Althea, the company's pharmaceutical business, offers a comprehensive range of cannabis-based medicines which are made available to patients via prescription. Peak Processing Solutions, AGH's recreational cannabis business, produces legal cannabis products purchased by adult consumers in retail stores.

AGH operates in highly regulated and legal cannabis markets across the world with burgeoning operations in Europe, North America, Australia and Africa.

To learn more about Althea Group Holdings, please visit: www.altheagroupholdings.com

For more information on Peak, please visit: www.peakprocessing.com

For more information on Althea, please visit: www.althea.life

